Novartis has unveiled its strategy to establish a radioligand therapy (RLT) manufacturing center in Denton, Texas. This facility represents the company’s inaugural production site in the state and its fifth RLT-focused location within the U.S. national grid. The project is a key component of the firm’s ongoing 23-billion-dollar investment initiative in the United States.
Project scope and timeline The 46,000-square-foot facility is scheduled to begin construction within the current year. Operations are projected to commence in 2028, creating specialized roles in bioengineering, advanced manufacturing, and quality operations. The establishment of this site is anticipated to stimulate economic development and employment opportunities throughout the Dallas-Fort Worth metropolitan area.
The significance of RLT technology Radioligand therapy functions as a precision oncology treatment, utilizing targeted radiation to interact directly with malignant cells throughout the patient’s body. Because these treatments are customized for individuals and possess a highly time-sensitive shelf life, geographical proximity between production sites and medical centers is vital for maintaining delivery speed.
Logistics network and clinical outlook The Texas site will integrate into an existing domestic network that includes facilities in New Jersey, Indiana, California, and a planned site in Florida. Maintaining a delivery reliability rate exceeding 99%, this manufacturing infrastructure supports the development of treatments for various cancers, including prostate, breast, lung, brain, and pancreatic malignancies. Texas state officials view this investment as a move to solidify the region’s status as a biotech hub while securing critical medical supply chains.